{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:07:15Z","timestamp":1790719635861,"version":"4.1.0"},"reference-count":78,"publisher":"Bentham Science Publishers Ltd.","issue":"12","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2020,12,30]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>As a kind of haemoglobin, cytochrome P450 enzymes (CYP450) participate in the metabolism of many\nsubstances, including endogenous substances, exogenous substances and drugs. It is estimated that 60% of common\nprescription drugs require bioconversion through CYP450. The influence of macrolides on CYP450 contributes to\nthe metabolism and drug-drug interactions (DDIs) of macrolides. At present, most studies on the effects of macrolides\non CYP450 are focused on CYP3A, but a few exist on other enzymes and drug combinations, such as telithromycin,\nwhich can decrease the activity of hepatic CYP1A2 and CYP3A2. This article summarizes some published\napplications of the influence of macrolides on CYP450 and the DDIs of macrolides caused by CYP450. And the\narticle may subsequently guide the rational use of drugs in clinical trials. To a certain extent, poisoning caused by\nadverse drug interactions can be avoided. Unreasonable use of macrolide antibiotics may enable the presence of\nresidue of macrolide antibiotics in animal-origin food. It is unhealthy for people to eat food with macrolide antibiotic\nresidues. So it is of great significance to guarantee food safety and protect the health of consumers by the rational use\nof macrolides. This review gives a detailed description of the influence of macrolides on CYP450 and the DDIs of\nmacrolides caused by CYP450. Moreover, it offers a perspective for researchers to further explore in this area.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389200221666200817113920","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T07:32:26Z","timestamp":1597822346000},"page":"928-937","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["A Review: Effects of Macrolides on CYP450 Enzymes"],"prefix":"10.2174","volume":"21","author":[{"given":"Liyun","family":"Zhang","sequence":"first","affiliation":[{"name":"National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agricultural University, Wuhan, Hubei 430070, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Xu","sequence":"additional","affiliation":[{"name":"National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agricultural University, Wuhan, Hubei 430070, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Badawy","sequence":"additional","affiliation":[{"name":"National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agricultural University, Wuhan, Hubei 430070, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awais","family":"Ihsan","sequence":"additional","affiliation":[{"name":"National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agricultural University, Wuhan, Hubei 430070, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenli","family":"Liu","sequence":"additional","affiliation":[{"name":"National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agricultural University, Wuhan, Hubei 430070, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changqing","family":"Xie","sequence":"additional","affiliation":[{"name":"National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agricultural University, Wuhan, Hubei 430070, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[{"name":"National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agricultural University, Wuhan, Hubei 430070, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfei","family":"Tao","sequence":"additional","affiliation":[{"name":"National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agricultural University, Wuhan, Hubei 430070, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1177\/00912700122012724","volume":"41","author":"Venkatakrishnan K.","year":"2001","unstructured":"Venkatakrishnan K.; Von Moltke L.L.; Greenblatt D.J.; Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 2001,41(11),1149-1179","journal-title":"J Clin Pharmacol"},{"key":"ref=2","first-page":"153","volume":"3","author":"Qingzhong Y.U.","year":"2006","unstructured":"Qingzhong Y.U.; Han J.; Gao X.; Advances in the research of the correlation between CYP450 and lung cancer. J Med Mol Biol 2006,3,153-155","journal-title":"J Med Mol Biol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.6026\/97320630003198","volume":"3","author":"Saxena A.","year":"2008","unstructured":"Saxena A.; Tripathi K.P.; Roy S.; Khan F.; Sharma A.; Pharmacovigilance: effects of herbal components on human drugs interactions involving cytochrome P450. Bioinformation 2008,3(5),198-204","journal-title":"Bioinformation"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00216-008-2291-6","volume":"392","author":"Zanger U.M.","year":"2008","unstructured":"Zanger U.M.; Turpeinen M.; Klein K.; Schwab M.; Functional pharmacogenetics\/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008,392(6),1093-1108","journal-title":"Anal Bioanal Chem"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1124\/dmd.30.12.1311","volume":"30","author":"Yuan R.","year":"2002","unstructured":"Yuan R.; Madani S.; Wei X-X.; Reynolds K.; Huang S-M.; Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 2002,30(12),1311-1319","journal-title":"Drug Metab Dispos"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/BF02353474","volume":"24","author":"Wrighton S.A.","year":"1996","unstructured":"Wrighton S.A.; VandenBranden M.; Ring B.J.; The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharm 1996,24(5),461-473","journal-title":"J Pharmacokinet Biopharm"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.1021\/acs.molpharmaceut.8b00787","volume":"15","author":"Fang Y.","year":"2018","unstructured":"Fang Y.; Gao J.; Wang T.; Tian X.; Gao N.; Zhou J.; Zhang H-F.; Wen Q.; Jin H.; Xing Y-R.; Qiao H.L.; Intraindividual variation and correlation of cytochrome P450 activities in human liver microsomes. Mol Pharm 2018,15(11),5312-5318","journal-title":"Mol Pharm"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1080\/1062936X.2019.1653966","volume":"30","author":"Dmitriev A.V.","year":"2019","unstructured":"Dmitriev A.V.; Filimonov D.A.; Rudik A.V.; Pogodin P.V.; Karasev D.A.; Lagunin A.A.; Poroikov V.V.; Drug-drug interaction prediction using PASS. SAR QSAR Environ Res 2019,30(9),655-664","journal-title":"SAR QSAR Environ Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1365-2885.1994.tb00271.x","volume":"17","author":"Baggot J.D.","year":"1994","unstructured":"Baggot J.D.; McKellar Q.A.; The absorption, distribution and elimination of anthelmintic drugs: the role of pharmacokinetics. J Vet Pharmacol Ther 1994,17(6),409-419","journal-title":"J Vet Pharmacol Ther"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/nrd1851","volume":"4","author":"Wienkers L.C.","year":"2005","unstructured":"Wienkers L.C.; Heath T.G.; Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 2005,4(10),825-833","journal-title":"Nat Rev Drug Discov"},{"key":"ref=11","first-page":"215","volume":"38","author":"Liu Y.Q.","year":"2009","unstructured":"Liu Y.Q.; Hong Y.J.; Zeng S.; [Recent advances in metabolism-based drug-drug interactions] Zhejiang Da Xue Xue Bao Yi Xue Ban 2009,38(2),215-224","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1002\/jps.22652","volume":"100","author":"Sugimoto H.","year":"2011","unstructured":"Sugimoto H.; Matsumoto S.; Tachibana M.; Niwa S.; Hirabayashi H.; Amano N.; Moriwaki T.; Establishment of in vitro P-glycoprotein inhibition assay and its exclusion criteria to assess the risk of drug-drug interaction at the drug discovery stage. J Pharm Sci 2011,100(9),4013-4023","journal-title":"J Pharm Sci"},{"key":"ref=13","first-page":"52","volume":"38","author":"Ai C.H.","year":"2011","unstructured":"Ai C.H.; Li H.; Dong D.L.; CYP450 induction based drug-drug interaction and evaluation methodology. J Int Pharm Res 2011,38,52-57","journal-title":"J Int Pharm Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/1099-081X(200005)21:4<157:AID-BDD226>3.0.CO;2-C","volume":"21","author":"Bu S.","year":"2000","unstructured":"Bu S.; Kim Y.; Kim S.; Lee M.; Effects of enzyme inducers and inhibitor on the pharmacokinetics of intravenous 2-(allylthio)pyrazine, a new chemoprotective agent, in rats. Biopharm Drug Dispos 2000,21(4),157-164","journal-title":"Biopharm Drug Dispos"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1211\/0022357055704","volume":"57","author":"Bae S.K.","year":"2005","unstructured":"Bae S.K.; Lee S.J.; Kim Y.H.; Kim T.; Lee M.G.; Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous ipriflavone in rats. J Pharm Pharmacol 2005,57,443-452","journal-title":"J Pharm Pharmacol"},{"key":"ref=16","first-page":"3524","volume":"40","author":"Lu T.L.","year":"2015","unstructured":"Lu T.L.; Su L.L.; Ji D.; Gu W.; Mao C.Q.; [Interaction between CYP450 enzymes and metabolism of traditional Chinese medicine as well as enzyme activity assay] Zhongguo Zhongyao Zazhi 2015,40(18),3524-3529","journal-title":"Zhongguo Zhongyao Zazhi"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/pds.4873","volume":"28","author":"Bonaldo G.","year":"2019","unstructured":"Bonaldo G.; Andriani L.A.; D\u2019Annibali O.; Motola D.; Vaccheri A.; Cardiovascular safety of macrolide and fluoroquinolone antibiotics: an analysis of the WHO database of adverse drug reactions. Pharmacoepidem Drug Saf 2019,28,1457-1463","journal-title":"Pharmacoepidem Drug Saf"},{"key":"ref=18","first-page":"137","volume":"97","author":"Taniguchi K.","year":"1999","unstructured":"Taniguchi K.; Nakamura A.; Tsurubuchi K.; Ishii A.; O\u2019Hara K.; Sawai T.; Appearance in Japan of highly macrolide-resistant Escherichia coli producing macrolide 2\u2032-phosphotransferase II. Microbios 1999,97(388),137-144","journal-title":"Microbios"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1023\/A:1006605725619","volume":"17","author":"Yatsunami J.","year":"1999","unstructured":"Yatsunami J.; Fukuno Y.; Nagata M.; Tominaga M.; Aoki S.; Tsuruta N.; Kawashima M.; Taniguchi S.; Hayashi S.; Antiangiogenic and antitumor effects of 14-membered ring macrolides on mouse B16 melanoma cells. Clin Exp Metastasis 1999,17(4),361-367","journal-title":"Clin Exp Metastasis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1378\/chest.122.6.2137","volume":"122","author":"Li Y.","year":"2002","unstructured":"Li Y.; Azuma A.; Takahashi S.; Usuki J.; Matsuda K.; Aoyama A.; Kudoh S.; Fourteen-membered ring macrolides inhibit vascular cell adhesion molecule 1 messenger RNA induction and leukocyte migration: role in preventing lung injury and fibrosis in bleomycin-challenged mice. Chest 2002,122(6),2137-2145","journal-title":"Chest"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/S0024-3205(01)01499-0","volume":"70","author":"Bray B.J.","year":"2002","unstructured":"Bray B.J.; Brennan N.J.; Perry N.B.; Menkes D.B.; Rosengren R.J.; Short term treatment with St. John\u2019s wort, hypericin or hyperforin fails to induce CYP450 isoforms in the Swiss Webster mouse. Life Sci 2002,70(11),1325-1335","journal-title":"Life Sci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1067\/mcp.2003.29","volume":"73","author":"Lowry J.A.","year":"2003","unstructured":"Lowry J.A.; Kearns G.L.; Abdel-Rahman S.M.; Nafziger A.N.; Khan I.S.; Kashuba A.D.; Schuetz E.G.; Bertino J.S.; van den Anker J.N.; Leeder J.S.; Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo. Clin Pharmacol Ther 2003,73(3),209-222","journal-title":"Clin Pharmacol Ther"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/j.1552-4604.1997.tb04287.x","volume":"37","author":"Wong S.L.","year":"1997","unstructured":"Wong S.L.; Cao G.; Mack R.J.; Granneman G.R.; The effect of erythromycin on the CYP3A component of sertindole clearance in healthy volunteers. J Clin Pharmacol 1997,37(11),1056-1061","journal-title":"J Clin Pharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1292\/jvms.71.1151","volume":"71","author":"Shah S.S.","year":"2009","unstructured":"Shah S.S.; Sasaki K.; Hayashi Y.; Motoyama S.; Helmi A.R.; Khalil W.F.; Shimoda M.; Inhibitory effects of ketoconazole, cimetidine and erythromycin on hepatic CYP3A activities in cats. J Vet Med Sci 2009,71(9),1151-1159","journal-title":"J Vet Med Sci"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1111\/bcp.13092","volume":"82","author":"Parasrampuria D.A.","year":"2016","unstructured":"Parasrampuria D.A.; Mendell J.; Shi M.; Matsushima N.; Zahir H.; Truitt K.; Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. Br J Clin Pharmacol 2016,82(6),1591-1600","journal-title":"Br J Clin Pharmacol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2133\/dmpk.DMPK-12-RG-134","volume":"28","author":"Akiyoshi T.","year":"2013","unstructured":"Akiyoshi T.; Ito M.; Murase S.; Miyazaki M.; Guengerich F.P.; Nakamura K.; Yamamoto K.; Ohtani H.; Mechanism-based inhibition profiles of erythromycin and clarithromycin with cytochrome P450 3A4 genetic variants. Drug Metab Pharmacokinet 2013,28(5),411-415","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1124\/dmd.106.009969","volume":"34","author":"McGinnity D.F.","year":"2006","unstructured":"McGinnity D.F.; Berry A.J.; Kenny J.R.; Grime K.; Riley R.J.; Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab Dispos 2006,34(8),1291-1300","journal-title":"Drug Metab Dispos"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3109\/00498259609050259","volume":"26","author":"Yamazaki H.","year":"1996","unstructured":"Yamazaki H.; Hiroki S.; Urano T.; Inoue K.; Shimada T.; Effects of roxithromycin, erythromycin and troleandomycin on their N-demethylation by rat and human cytochrome P450 enzymes. Xenobiotica 1996,26(11),1143-1153","journal-title":"Xenobiotica"},{"key":"ref=29","first-page":"776","volume":"23","author":"Freeman D.J.","year":"1987","unstructured":"Freeman D.J.; Martell R.; Carruthers S.G.; Heinrichs D.; Keown P.A.; Stiller C.R.; Cyclosporin-erythromycin interaction in normal subjects. Br J Clin Pharmacol 1987,23(6),776-778","journal-title":"Br J Clin Pharmacol"},{"key":"ref=30","first-page":"1315","volume":"23","author":"Lampen A.","year":"1995","unstructured":"Lampen A.; Christians U.; Guengerich F.P.; Watkins P.B.; Kolars J.C.; Bader A.; Gonschior A-K.; Dralle H.; Hackbarth I.; Sewing K-F.; Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995,23(12),1315-1324","journal-title":"Drug Metab Dispos"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejpb.2014.06.019","volume":"88","author":"G\u0142\u00f3wka E.","year":"2014","unstructured":"G\u0142\u00f3wka E.; Wosicka-Fr\u0105ckowiak H.; Hyla K.; Stefanowska J.; Jastrz\u0119bska K.; Klapiszewski \u0141.; Jesionowski T.; Cal K.; Polymeric nanoparticles-embedded organogel for roxithromycin delivery to hair follicles. Eur J Pharm Biopharm 2014,88(1),75-84","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.powtec.2006.07.016","volume":"169","author":"Biradar S.V.","year":"2006","unstructured":"Biradar S.V.; Patil A.R.; Sudarsan G.V.; Pokharkar V.B.; A comparative study of approaches used to improve solubility of roxithromycin. Powder Technol 2006,169,22-32","journal-title":"Powder Technol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2478\/s11536-009-0113-7","volume":"5","author":"Ostrowski M.","year":"2010","unstructured":"Ostrowski M.; Wilkowska E.; B\u0105czek T.; Impact of pharmaceutical dosage form on stability and dissolution of roxithromycin. Open Med 2010,5,83-90","journal-title":"Open Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/bcpt.12668","volume":"120","author":"Qin Y.","year":"2017","unstructured":"Qin Y.; Xu W.; Mo L.; Li X.; Ge B.; Xiong J.; Gao L.; Xu P.; Xue M.; Comparison of pharmacokinetics and tissue distribution kinetics of roxithromycin and expression of CYP 3A1 between pregnant mice and foetuses. Basic Clin Pharmacol Toxicol 2017,120(2),146-151","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/01.ftd.0000249943.85160.13","volume":"28","author":"Kaufmann P.","year":"2006","unstructured":"Kaufmann P.; Haschke M.; T\u00f6r\u00f6k M.; Beltinger J.; Bogman K.; Wenk M.; Terracciano L.; Kr\u00e4henb\u00fchl S.; Mechanisms of venoocclusive disease resulting from the combination of cyclophosphamide and roxithromycin. Ther Drug Monit 2006,28(6),766-774","journal-title":"Ther Drug Monit"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/00007691-199001000-00012","volume":"12","author":"Birkett D.J.","year":"1990","unstructured":"Birkett D.J.; Robson R.A.; Grgurinovich N.; Tonkin A.; Single oral dose pharmacokinetics of erythromycin and roxithromycin and the effects of chronic dosing. Ther Drug Monit 1990,12(1),65-71","journal-title":"Ther Drug Monit"},{"key":"ref=37","author":"Aceva R.","unstructured":"Aceva R.; Blazevska T.; Malinkov I.; Darkovska-Serafimovska M.; Gjorgjev A.; Arsova-Sarafinovska Z.; A study of the interaction of roxithromycin with theophylline in asthma patients. In 35th International Medical Scientific Congress for medical students and young doctors","journal-title":"35th International Medical Scientific Congress for medical students and young doctors"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jpeds.2010.02.007","volume":"157","author":"Francavilla R.","year":"2010","unstructured":"Francavilla R.; Lionetti E.; Castellaneta S.; Margiotta M.; Piscitelli D.; Lorenzo L.; Cavallo L.; Ierardi E.; Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. J Pediatr 2010,157(2),228-232","journal-title":"J Pediatr"},{"key":"ref=39","first-page":"1023","volume":"29","author":"Bruce M.A.","year":"2001","unstructured":"Bruce M.A.; Hall S.D.; Haehner-Daniels B.D.; Gorski J.C.; In vivo effect of clarithromycin on multiple cytochrome P450s. Drug Metab Dispos 2001,29(7),1023-1028","journal-title":"Drug Metab Dispos"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2174\/187231210791292717","volume":"4","author":"Michaud V.","year":"2010","unstructured":"Michaud V.; Turgeon J.; Assessment of competitive and mechanism-based inhibition by clarithromycin: use of domperidone as a CYP3A probe-drug substrate and various enzymatic sources including a new cell-based assay with freshly isolated human hepatocytes. Drug Metab Lett 2010,4(2),69-76","journal-title":"Drug Metab Lett"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2165\/00003088-200039030-00003","volume":"39","author":"Kuper J.I.","year":"2000","unstructured":"Kuper J.I.; D\u2019Aprile M.; Drug-drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet 2000,39(3),203-214","journal-title":"Clin Pharmacokinet"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1208\/s12248-016-0009-9","volume":"19","author":"Moj D.","year":"2017","unstructured":"Moj D.; Hanke N.; Britz H.; Frechen S.; Kanacher T.; Wendl T.; Haefeli W.E.; Lehr T.; Clarithromycin, midazolam, and digoxin: application of PBPK modeling to gain new insights into drug-drug interactions and co-medication regimens. AAPS J 2017,19(1),298-312","journal-title":"AAPS J"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1472-8206.1991.tb00738.x","volume":"5","author":"Uzzan B.","year":"1991","unstructured":"Uzzan B.; Nicolas P.; Perret G.; Vassy R.; Tod M.; Petitjean O.; Effects of troleandomycin and josamycin on thyroid hormone and steroid serum levels, liver function tests and microsomal monooxygenases in healthy volunteers: a double blind placebo-controlled study. Fundam Clin Pharmacol 1991,5(6),513-526","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/S0006-2952(99)00410-4","volume":"59","author":"Huang Z.","year":"2000","unstructured":"Huang Z.; Roy P.; Waxman D.J.; Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 2000,59(8),961-972","journal-title":"Biochem Pharmacol"},{"key":"ref=45","first-page":"43","volume":"45","author":"Sheng L.","year":"2010","unstructured":"Sheng L.; Tan W.; Hu J.P.; Chen H.; Li Y.; [Effect of CYP3A and P-glycoprotein on the absorption of buagafuran in rat intestinal lumen] Yao Xue Xue Bao 2010,45(1),43-48","journal-title":"Yao Xue Xue Bao"},{"key":"ref=46","first-page":"1391","volume":"28","author":"Ledirac N.","year":"2000","unstructured":"Ledirac N.; de Sousa G.; Fontaine F.; Agouridas C.; Gugenheim J.; Lorenzon G.; Rahmani R.; Effects of macrolide antibiotics on CYP3A expression in human and rat hepatocytes: interspecies differences in response to troleandomycin. Drug Metab Dispos 2000,28(12),1391-1393","journal-title":"Drug Metab Dispos"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.bcp.2013.05.015","volume":"86","author":"Grimsley A.","year":"2013","unstructured":"Grimsley A.; Gallagher R.; Hutchison M.; Pickup K.; Wilson I.D.; Samuelsson K.; Drug-drug interactions and metabolism in cytochrome P450 2C knockout mice: application to troleandomycin and midazolam. Biochem Pharmacol 2013,86(4),529-538","journal-title":"Biochem Pharmacol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"861","DOI":"10.3109\/03639040903551319","volume":"36","author":"Togami K.","year":"2010","unstructured":"Togami K.; Chono S.; Seki T.; Morimoto K.; Aerosol-based efficient delivery of telithromycin, a ketolide antimicrobial agent, to lung epithelial lining fluid and alveolar macrophages for treatment of respiratory infections. Drug Dev Ind Pharm 2010,36(7),861-866","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1093\/jac\/46.5.741","volume":"46","author":"Edlund C.","year":"2000","unstructured":"Edlund C.; Alv\u00e1n G.; Barkholt L.; Vacheron F.; Nord C.E.; Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora. J Antimicrob Chemother 2000,46(5),741-749","journal-title":"J Antimicrob Chemother"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.eimc.2009.06.002","volume":"27","author":"Cobos-Trigueros N.","year":"2009","unstructured":"Cobos-Trigueros N.; Ateka O.; Pitart C.; Vila J.; [Macrolides and ketolides] Enferm Infecc Microbiol Clin 2009,27(7),412-418","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ejps.2012.04.003","volume":"47","author":"Sharma P.","year":"2012","unstructured":"Sharma P.; Butters C.J.; Smith V.; Elsby R.; Surry D.; Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins. Eur J Pharm Sci 2012,47(1),244-255","journal-title":"Eur J Pharm Sci"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1124\/dmd.107.020198","volume":"36","author":"Reese M.J.","year":"2008","unstructured":"Reese M.J.; Wurm R.M.; Muir K.T.; Generaux G.T.; St John-Williams L.; McConn D.J.; An in vitro mechanistic study to elucidate the desipramine\/bupropion clinical drug-drug interaction. Drug Metab Dispos 2008,36(7),1198-1201","journal-title":"Drug Metab Dispos"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1177\/0091270009336444","volume":"50","author":"Gr\u00f6nlund J.","year":"2010","unstructured":"Gr\u00f6nlund J.; Saari T.; Hagelberg N.; Martikainen I.K.; Neuvonen P.J.; Olkkola K.T.; Laine K.; Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone. J Clin Pharmacol 2010,50(1),101-108","journal-title":"J Clin Pharmacol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.lfs.2005.12.022","volume":"79","author":"Nosaka H.","year":"2006","unstructured":"Nosaka H.; Nadai M.; Kato M.; Yasui K.; Yoshizumi H.; Miyoshi M.; Zhao Y.L.; Baba K.; Takagi K.; Hasegawa T.; Effect of a newly developed ketolide antibiotic, telithromycin, on metabolism of theophylline and expression of cytochrome P450 in rats. Life Sci 2006,79(1),50-56","journal-title":"Life Sci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3109\/00498250903470248","volume":"40","author":"Lee J.H.","year":"2010","unstructured":"Lee J.H.; Kang H.E.; Lee M.G.; Pharmacokinetic interaction between telithromycin and metformin in diabetes mellitus rats. Xenobiotica 2010,40(3),217-224","journal-title":"Xenobiotica"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1080\/1120009X.2019.1623361","volume":"31","author":"Golikova M.V.","year":"2019","unstructured":"Golikova M.V.; Strukova E.N.; Portnoy Y.A.; Dovzhenko S.A.; Kobrin M.B.; Zinner S.H.; Firsov A.A.; Resistance studies with Streptococcus pneumoniae using an in vitro dynamic model: amoxicillin versus azithromycin at clinical exposures. J Chemother 2019,31(5),252-260","journal-title":"J Chemother"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/bdd.1900","volume":"35","author":"Togami K.","year":"2014","unstructured":"Togami K.; Hayashi Y.; Chono S.; Morimoto K.; Involvement of intestinal permeability in the oral absorption of clarithromycin and telithromycin. Biopharm Drug Dispos 2014,35(6),321-329","journal-title":"Biopharm Drug Dispos"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/bcp.12668","volume":"80","author":"Greenblatt D.J.","year":"2015","unstructured":"Greenblatt D.J.; Harmatz J.S.; Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies. Br J Clin Pharmacol 2015,80(3),342-350","journal-title":"Br J Clin Pharmacol"},{"key":"ref=59","first-page":"879","volume":"32","author":"Fan X-M.","year":"2017","unstructured":"Fan X-M.; Efficiency of azithromycin and tobramycin drug combination on Pseudomonas aeruginosa. Lab Med 2017,32,879-882","journal-title":"Lab Med"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1128\/AAC.00788-06","volume":"51","author":"Soltow S.M.","year":"2007","unstructured":"Soltow S.M.; Brenner G.M.; Synergistic activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. Antimicrob Agents Chemother 2007,51(1),23-27","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jpba.2004.06.010","volume":"36","author":"Civitareale C.","year":"2004","unstructured":"Civitareale C.; Fiori M.; Ballerini A.; Brambilla G.; Identification and quantification method of spiramycin and tylosin in feedingstuffs with HPLC-UV\/DAD at 1 ppm level. J Pharm Biomed Anal 2004,36(2),317-325","journal-title":"J Pharm Biomed Anal"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00002018-199513020-00005","volume":"13","author":"von Rosensteil N.A.","year":"1995","unstructured":"von Rosensteil N.A.; Adam D.; Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf 1995,13(2),105-122","journal-title":"Drug Saf"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"262","DOI":"10.2174\/157341211797458032","volume":"7","author":"Kit C.W.","year":"2011","unstructured":"Kit C.W.; Segarra I.; Simultaneous HPLC determination of metronidazole and spiramycin in plasma and brain of mouse. Curr Pharm Anal 2011,7,262-267","journal-title":"Curr Pharm Anal"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/0394632015593232","volume":"29","author":"El-Mahmoudy A.","year":"2016","unstructured":"El-Mahmoudy A.; Gheith I.; The anti-nociceptive potential of tilmicosin against chemical-induced but not thermal-induced pain in mice. Int J Immunopathol Pharmacol 2016,29(1),9-16","journal-title":"Int J Immunopathol Pharmacol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1038\/sj.ki.5000325","volume":"69","author":"Eng H-S.","year":"2006","unstructured":"Eng H-S.; Mohamed Z.; Calne R.; Lang C.C.; Mohd M.A.; Seet W-T.; Tan S-Y.; The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients. Kidney Int 2006,69(10),1858-1864","journal-title":"Kidney Int"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1128\/AAC.31.11.1843","volume":"31","author":"Misu T.","year":"1987","unstructured":"Misu T.; Arai S.; Furukawa M.; Yamamoto Y.; Miyazaki T.; Effects of rokitamycin and other macrolide antibiotics on Mycoplasma pneumoniae in L cells. Antimicrob Agents Chemother 1987,31(11),1843-1845","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1002\/jps.22382","volume":"100","author":"Gavini E.","year":"2011","unstructured":"Gavini E.; Rassu G.; Ferraro L.; Generosi A.; Rau J.V.; Brunetti A.; Giunchedi P.; Dalpiaz A.; Influence of chitosan glutamate on the in vivo intranasal absorption of rokitamycin from microspheres. J Pharm Sci 2011,100(4),1488-1502","journal-title":"J Pharm Sci"},{"key":"ref=68","first-page":"776","volume":"27","author":"Zhao X-J.","year":"1999","unstructured":"Zhao X-J.; Koyama E.; Ishizaki T.; An in vitro study on the metabolism and possible drug interactions of rokitamycin, a macrolide antibiotic, using human liver microsomes. Drug Metab Dispos 1999,27(7),776-785","journal-title":"Drug Metab Dispos"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/jac\/24.4.551","volume":"24","author":"Miura T.","year":"1989","unstructured":"Miura T.; Iwasaki M.; Komori M.; Ohi H.; Kitada M.; Mitsui H.; Kamataki T.; Decrease in a constitutive form of cytochrome P-450 by macrolide antibiotics. J Antimicrob Chemother 1989,24(4),551-559","journal-title":"J Antimicrob Chemother"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1134\/S1023193511070056","volume":"47","author":"Drljevi\u0107-Djuri\u0107 K.","year":"2011","unstructured":"Drljevi\u0107-Djuri\u0107 K.; Ivi\u0107 M.A.; Petrovi\u0107 S.D.; Mijin D.; Jadranin M.; A voltammetric method for the quantitative determination of midecamycin compared to its simultaneous HPLC determination. Russ J Electrochem 2011,47,781-786","journal-title":"Russ J Electrochem"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s002280050253","volume":"52","author":"Alfonso I.","year":"1997","unstructured":"Alfonso I.; Alcalde G.; Garc\u00eda-S\u00e1iz M.; de Cos M.A.; Mediavilla A.; Interaction between cyclosporine A and midecamycin. Eur J Clin Pharmacol 1997,52(1),79-80","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"53506","DOI":"10.1074\/jbc.M401625200","volume":"279","author":"Lovmar M.","year":"2004","unstructured":"Lovmar M.; Tenson T.; Ehrenberg M.; Kinetics of macrolide action: the josamycin and erythromycin cases. J Biol Chem 2004,279(51),53506-53515","journal-title":"J Biol Chem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2133\/dmpk.19.55","volume":"19","author":"Naritomi Y.","year":"2004","unstructured":"Naritomi Y.; Teramura Y.; Terashita S.; Kagayama A.; Utility of microtiter plate assays for human cytochrome P450 inhibition studies in drug discovery: application of simple method for detecting quasi-irreversible and irreversible inhibitors. Drug Metab Pharmacokinet 2004,19(1),55-61","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1111\/j.1528-1157.1995.tb06007.x","volume":"36","author":"Levy R.H.","year":"1995","unstructured":"Levy R.H.; Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1995,36(Suppl. 5),S8-S13","journal-title":"Epilepsia"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/jaoac\/92.3.975","volume":"92","author":"Granja R.","year":"2009","unstructured":"Granja R.; Ni\u00f1o A.M.; Zucchetti R.; Ni\u00f1o R.M.; Patel R.; Salerno A.G.; Determination of erythromycin and tylosin residues in honey by LC\/MS\/MS. J AOAC Int 2009,92(3),975-980","journal-title":"J AOAC Int"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/(SICI)1097-0231(20000229)14:4<207:AID-RCM863>3.0.CO;2-#","volume":"14","author":"Chu I.","year":"2000","unstructured":"Chu I.; Favreau L.; Soares T.; Lin Cc.; Nomeir A.A.; Validation of higher-throughput high-performance liquid chromatography\/atmospheric pressure chemical ionization tandem mass spectrometry assays to conduct cytochrome P450s CYP2D6 and CYP3A4 enzyme inhibition studies in human liver microsomes. Rapid Commun Mass Spectrom 2000,14(4),207-214","journal-title":"Rapid Commun Mass Spectrom"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.catcom.2010.12.031","volume":"12","author":"Jiang J.","year":"2011","unstructured":"Jiang J.; Wang J.; Cai H.; Li K.; Deng Y.; CYP3As catalyze nifedipine oxidation in pig liver microsomes: enzyme kinetics, inhibition and functional expression. Catal Commun 2011,12,694-697","journal-title":"Catal Commun"},{"key":"ref=78","first-page":"253","volume":"14","author":"Persi\u0107-Vojinovi\u0107 S.","year":"2006","unstructured":"Persi\u0107-Vojinovi\u0107 S.; Milavec-Pureti\u0107 V.; Dobri\u0107 I.; Rados J.; Spoljar S.; Disseminated Hailey-Hailey disease treated with topical tacrolimus and oral erythromycin: case report and review of the literature. Acta Dermatovenerol Croat 2006,14(4),253-257","journal-title":"Acta Dermatovenerol Croat"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/184894","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/184894\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/184894","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T23:35:36Z","timestamp":1634340936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/184894\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,30]]},"references-count":78,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,30]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389200221666200817113920","relation":{},"ISSN":["1389-2002"],"issn-type":[{"value":"1389-2002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,30]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}